Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function.

Jensen SBK, Juhl CR, Janus C, Lundgren JR, Martinussen C, Wiingaard C, Knudsen C, Frikke-Schmidt R, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS

Obesity (Silver Spring, Md.)1 Apr 2023Cited by 15 (Europe PMC)

PMID36942420DOI10.1002/oby.23715PepBankPUB-36942420

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, liraglutide 3.0 mg/d alone lowered postprandial glucose response by 7% versus placebo.
In plain wordsIn adults with obesity after weight loss, liraglutide alone lowered the blood sugar rise after meals more than placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg/d · 52 weeksAs given in this study (human).
Measurements
Postprandial glucose response change
−7%
liraglutide vs placebo
Source sentences
Summary
Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
Report a problemFND-3694242004
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, liraglutide 3.0 mg/d alone did not improve beta cell function versus placebo.
In plain wordsIn adults with obesity after weight loss, liraglutide alone did not improve beta cell function compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeBeta cell function (disposition index)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
Report a problemFND-3694242005
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, liraglutide 3.0 mg/d alone did not change glucagon response versus placebo.
In plain wordsIn adults with obesity after weight loss, liraglutide alone did not change the glucagon response compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeGlucagon response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide alone improved postprandial glucose response by -7% (95% CI: -12% to -1%; p = 0.018), but not beta cell function or glucagon.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
Report a problemFND-3694242006

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, 52 weeks of exercise plus liraglutide lowered postprandial glucose response by 9% versus placebo.
In plain wordsIn adults with obesity after weight loss, exercise plus liraglutide lowered the blood sugar rise after meals more than placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Postprandial glucose response change
−9%
exercise plus liraglutide vs placebo
Source sentences
Summary
After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3694242001
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, exercise plus liraglutide improved beta cell function by 49% versus placebo.
In plain wordsIn adults with obesity after weight loss, exercise plus liraglutide improved beta cell function more than placebo.
Peptide
Liraglutide
Outcome
IncreaseBeta cell function (disposition index)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Beta cell function change
49%
exercise plus liraglutide vs placebo
Source sentences
Summary
After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3694242002
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after diet-induced weight loss, exercise plus liraglutide decreased glucagon response by 18% versus placebo.
In plain wordsIn adults with obesity after weight loss, exercise plus liraglutide lowered the glucagon response more than placebo.
Peptide
Liraglutide
Outcome
DecreaseGlucagon response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Glucagon response change
−18%
exercise plus liraglutide vs placebo
Source sentences
Summary
After 1 year of treatment, the combination group had decreased postprandial glucose response by -9% (95% CI: -14% to -3%; p = 0.002), improved beta cell function by 49% (95% CI: 16% to 93%; p = 0.002), and decreased glucagon response by -18% (95% CI: -34% to -3%; p = 0.024) compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized placebo-controlled trial, adults with obesity (BMI: 32-43 kg/m² ) without diabetes underwent an 8-week low-calorie diet (800 kcal/d) and were randomized to 52 weeks of aerobic exercise, liraglutide 3.0 mg/d, exercise and liraglutide combined, or placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3694242003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.